Jin Chen

Deanna Edwards, PhD, left, Jin Chen, MD, PhD, and colleagues are studying a new therapeutic strategy for triple-negative breast cancer.
April 1, 2021

Breast cancer cells ‘steal’ nutrients from immune cells: study

Triple-negative breast cancer cells engage in a “glutamine steal” — outcompeting T cells for the nutrient glutamine and impairing their ability to kill tumor cells, Vanderbilt researchers have discovered.

By Leigh MacMillan
November 12, 2020

New therapeutic target for lung cancer

Vanderbilt researchers have identified a new molecular partner — and potential therapeutic target — in a signaling axis that drives lung cancer.

By Sarah E. Glass
August 20, 2020

A “torque” for tumor blood vessels

Vanderbilt scientists have discovered a new target for normalizing tumor blood vessels to improve cancer immunotherapies.

By Bill Snyder
April 14, 2016

Switching breast cancer off

Signaling by a receptor that is overexpressed in aggressive forms of breast cancer has been linked to glutamine metabolism, suggesting new anti-cancer therapeutic targets.

By Marilyn Holt
February 10, 2016

Overcoming lung cancer drug resistance

Vanderbilt investigators have discovered a way to overcome the resistance of some lung cancers to certain targeted therapies, which could lead to more effective treatments for lung cancer patients.

By Marilyn Holt
April 10, 2014

Study tracks new lung cancer drug target

Researchers at Vanderbilt University have identified a potential new drug target in subtypes of lung cancer that are difficult to treat.

By Bill Snyder